Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LPAR1 siRNA-LNP
- Development stage
- Preclinical
- Lead developer
- Nitto BioPharma
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
LPAR1 siRNA-LNP (NBF-008) is an investigational kidney-targeting small interfering RNA (siRNA) lipid nanoparticle (LNP) therapeutic developed by Nitto BioPharma. It is designed to selectively target and knock down the expression of lysophosphatidic acid receptor 1 (LPAR1), a G-protein coupled receptor that plays a critical role in tissue fibrosis and inflammation. By inhibiting LPAR1 expression, the therapeutic aims to attenuate kidney fibrosis and improve renal function. LPAR1 siRNA-LNP is currently in preclinical development for the treatment of chronic kidney disease (CKD), including diabetic kidney disease (DKD) and hypertensive CKD.
- Other names
- CedarLPAR1-targeting siRNA (Nitto BioPharma)
02
Targets
LPAR1 (Lysophosphatidic acid receptor 1)
Beyond the preview
Go deeper on LPAR1 siRNA-LNP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LPAR1 siRNA-LNP.